Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | LOX | P28300 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.44 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.44 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8033818 | 0.87 | HPGD (0.54) | HPGDCA2MEN1KMT2ALOX | |
| SCHEMBL13998433 | 0.86 | MAPK9 (0.48) | CA2MEN1KMT2ALOXCA1 | |
| SCHEMBL1742818 | 0.86 | HPGD (0.52) | HPGDCA2MEN1KMT2ALOX | |
| Hydrochloric Acid SCHEMBL28187724 | 0.86 | HPGD (0.52) | HPGDCA2MEN1KMT2ALOX | |
| SCHEMBL13881587 | 0.86 | MEN1 (0.54) | HPGDMEN1KMT2ALOXCCKBR | |
| SCHEMBL14519924 | 0.82 | MEN1 (0.52) | HPGDMEN1KMT2ALOXCCKBR | |
| SCHEMBL7460244 | 0.82 | CCKBR (0.50) | HPGDMEN1KMT2ALOXCCKBR | |
| SCHEMBL7451657 | 0.81 | MEN1 (0.51) | HPGDMEN1KMT2ALOXCCKBR | |
| SCHEMBL10341076 | 0.79 | ALDH1A1 (0.51) | CA2MEN1KMT2ALOXCA1 | |
| SCHEMBL12334602 | 0.78 | CCKBR (0.52) | HPGDMEN1KMT2ALOXCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3095784-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Inc. (US) | 2016-11-23 | — | — | EP | disclosed |
| US-9493431-B2 | Apoptosis-inducing agent for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-2387559-B1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-06-29 | — | — | EP | disclosed |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC (US) | 2016-01-07 | — | — | US | disclosed |
| US-9156856-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338466-B2 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| CN-102282128-A | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2387559-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | Abbott Laboratories (US) | 2011-11-23 | — | — | EP | disclosed |
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | US | disclosed |
| WO-2010083442-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBOTT LABORATORIES (US) | 2010-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184766-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HPGD 1466/4885CA2 2352/4885MEN1 3502/4885 |
| US-20160002187-A1 | APOPTOSIS-INDUCING AGENT FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HPGD 1633/4885CA2 2480/4885MEN1 3625/4885 |
| US-20130184278-A1 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | HPGD 1466/4885CA2 2352/4885MEN1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.